What is the clinical evidence from this study?

Study design: Observational. Population: Hypertriglyceridemia (n=41). Intervention: Hypertriglyceridemia and other dyslipidemias vs. Normolipidemic controls. Primary outcome: Postprandial remnant-like particle (RLP) lipemia measured as incremental area under the curve (IAUC).

July 1, 2001Open Access

Postprandial Remnant-like Lipoproteins in Hypertriglyceridemia1

Key Result

Postprandial remnant-like particle lipemia was enhanced in hypertriglyceridemic subjects compared with normolipidemic subjects, and was proportional to fasting RLP and triglyceride levels.

Study Design

Type

Observational (n=41)

Structured PICO

Population

41 subjects including 8 with hypertriglyceridemia, 14 with combined hyperlipidemia, 5 with apo E2/2 genotype, 10 normolipidemic controls, and 4 with hypercholesterolemia.

Comparator

Normolipidemic (NL) controls

Outcome

Postprandial remnant-like particle (RLP) cholesterol and triglycerides measured as incremental area under the curve (IAUC)surrogate

Postprandial remnant-like particle lipemia is enhanced in hypertriglyceridemia and its composition varies by hyperlipidemia subtype.

Abstract

It has been proposed that remnants of chylomicrons and very-low-density lipoproteins (VLDL) are atherogenic. We have used an immunochemical method to isolate remnant-like particles (RLP) and measured them in terms of their cholesterol and triglycerides (TG). RLP consist of apoB-48-containing triglyceride-rich lipoproteins and remnant-like VLDL containing apoB-100. The study aim was to look for information from postprandial RLP data that could not be known from other markers of triglyceride-rich lipoproteins and fasting TG and RLP data alone. A total of 41 subjects were studied. Eight subjects had hypertriglyceridemia (HTG) and low high-density lipoprotein (HDL), 14 had combined hyperlipidemia (CH), 5 had the apo E2/2 genotype receiving gemfibrozil, 10 were normolipidemic (NL) controls, and 4 had hypercholesterolemia. As a whole group, there was correlation among 1) fasting TG, RLP cholesterol (RLP-C), and RLP-TG but not VLDL apo B100, VLDL apo B48 and their respective postprandial responses measured as incremental area under the curve (IAUC), 2) fasting TG and postprandial IAUC of RLP-C and RLP-TG, 3) RLP-C IAUC, RLP-TG IAUC, and TG IAUC, retinyl palmitate (RP) IAUC, and VLDL apo B48 IAUC but not VLDL apo B100 IAUC. The HTG/low HDL-C and CH groups had higher IAUC for RLP-C, RLP-TG, TG, and RP than the NL group. Fasting and postprandial RLP were triglyceride enriched in the HTG/low HDL-C group and to a lesser extent in the CH group. The HTG/low HDL-C and CH groups had a delay in their RLP-C but not RLP-TG peaks suggesting a delay in hepatic clearance of RLP and/or a protracted period of lipolysis and/or processing of RLP. The fasting and postprandial RLP-C/RLP-TG and RLP-C/TG ratios were elevated in the apo E2/2 group in spite of gemfibrozil therapy. The increment in postprandial RLP was, however, not exaggerated. Our data indicate that 1) postprandial RLP lipemia is enhanced in HTG subjects when compared with NL subjects, 2) postprandial RLP lipemia is proportional to fasting RLP and TG levels and mirrors, to a large extent, increases in postprandial TG, RP, and VLDL apo B48 but not VLDL apo B100, 3) there are compositional differences in fasting and postprandial RLP in the three forms of HTG studied, RLP being triglyceride enriched in the HTG/low HDL-C group and to a lesser extent in the CH group, and cholesterol-enriched in the apo E2/2 group, and 4) apo E2/2 subjects had high fasting and postprandial RLP-C concentrations in spite of being on treatment with gemfibrozil and having normal fasting and postprandial TG concentrations.